ArticlePloS one2024
Multimodal feature fusion-based graph convolutional networks for Alzheimer's disease stage classification using F-18 florbetaben brain PET images and clinical indicators.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Leveraging spatial dependencies and multi-scale features for automated knee injury detection on MRI diagnosis.Frontiers in bioengineering and biotechnology · 2025Article
- Multimodal graph neural networks in healthcare: a review of fusion strategies across biomedical domains.Frontiers in artificial intelligence · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD), the most prevalent degenerative brain disease associated with dementia, requires early diagnosis to alleviate worsening of symptoms through appropriate management and treatment. Recent studies on AD stage classification are increasingly using multimodal data. However, few studies have applied graph neural networks to multimodal data comprising F-18 florbetaben (FBB) amyloid brain positron emission tomography (PET) images and clinical indicators. The objective of this study was to demonstrate the effectiveness of graph convolutional network (GCN) for AD stage classification using multimodal data, specifically FBB PET images and clinical indicators, collected from Dong-A University Hospital (DAUH) and Alzheimer's Disease Neuroimaging Initiative (ADNI). The effectiveness of GCN was demonstrated through comparisons with the support vector machine, random forest, and multilayer perceptron across four classification tasks (normal control (NC) vs. AD, NC vs. mild cognitive impairment (MCI), MCI vs. AD, and NC vs. MCI vs. AD). As input, all models received the same combined feature vectors, created by concatenating the PET imaging feature vectors extracted by the 3D dense convolutional network and non-imaging feature vectors consisting of clinical indicators using multimodal feature fusion method. An adjacency matrix for the population graph was constructed using cosine similarity or the Euclidean distance between subjects' PET imaging feature vectors and/or non-imaging feature vectors. The usage ratio of these different modal data and edge assignment threshold were tuned by setting them as hyperparameters. In this study, GCN-CS-com and GCN-ED-com were the GCN models that received the adjacency matrix constructed using cosine similarity (CS) and the Euclidean distance (ED) between the subjects' PET imaging feature vectors and non-imaging feature vectors, respectively. In modified nested cross validation, GCN-CS-com and GCN-ED-com respectively achieved average test accuracies of 98.40%, 94.58%, 94.01%, 82.63% and 99.68%, 93.82%, 93.88%, 90.43% for the four aforementioned classification tasks using DAUH dataset, outperforming the other models. Furthermore, GCN-CS-com and GCN-ED-com respectively achieved average test accuracies of 76.16% and 90.11% for NC vs. MCI vs. AD classification using ADNI dataset, outperforming the other models. These results demonstrate that GCN could be an effective model for AD stage classification using multimodal data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.